Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to ...

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted an opinion recommending the approval of ...

France's Sanofi said its Dupixent drug jointly developed with Regeneron advanced toward a new indication for chronic hives in the European Union, while the U.S. Food and Drug Administration extended ...

The FDA has approved a new injectable version of cancer drug Keytruda as Merck seeks to protect its market dominance.  Here are five things to know: ...

Tralokinumab self-administered by patients with atopic dermatitis via a pre-filled pen is a safe and effective treatment option.